UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000038333
Receipt number R000043686
Scientific Title Siteless Virtual Study for Validation of Adverse Events Monitoring Application in Oncology
Date of disclosure of the study information 2019/10/18
Last modified on 2020/04/17 10:06:22

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Siteless Virtual Study for Validation of Adverse Events Monitoring Application in Oncology

Acronym

ONCOLO Virtual Trial

Scientific Title

Siteless Virtual Study for Validation of Adverse Events Monitoring Application in Oncology

Scientific Title:Acronym

ONCOLO Virtual Trial

Region

Japan


Condition

Condition

cancer

Classification by specialty

Medicine in general Gastroenterology Hepato-biliary-pancreatic medicine
Pneumology Endocrinology and Metabolism Hematology and clinical oncology
Nephrology Neurology Surgery in general
Gastrointestinal surgery Hepato-biliary-pancreatic surgery Vascular surgery
Chest surgery Endocrine surgery Breast surgery
Obstetrics and Gynecology Dermatology Urology
Radiology Oral surgery

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

1. To validate of adverse events monitoring application
2. To research the change of QOL (Week0 to Week4)
3. To collect date by wearable device

Basic objectives2

Others

Basic objectives -Others

System validation

Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

1. System error rate (Week0 to Week4)
2. Input rate (Week0 to Week4)
3. QOL change rate (Week0 to Week4)
4. The date collected by wearable device (Week0 to Week4)

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

1 years-old <=

Age-upper limit

100 years-old >=

Gender

Male and Female

Key inclusion criteria

1. The subject is signing informed consent.
2. The subject can prove that they have had cancer.
3. The subject can understand Japanese.

Key exclusion criteria

The subject suspected of cognitive decline or psychiatric disorder that may be difficult to meet the requirements of this study

Target sample size

100


Research contact person

Name of lead principal investigator

1st name Kenta
Middle name
Last name Kachi

Organization

3H Clinical Trial Inc.

Division name

LIFTA for Oncology

Zip code

171-0022

Address

Ikebukuro YS Building 2F, 1-13-23 Minami-Ikebukuro, Toshima-Ku, Tokyo, Japan 171-0022

TEL

03-5985-0053

Email

info_oncolo@3h-ct.co.jp


Public contact

Name of contact person

1st name Yuki
Middle name
Last name Nakayama

Organization

3H Clinical Trial Inc.

Division name

LIFTA for Oncology

Zip code

171-0022

Address

Ikebukuro YS Building 2F, 1-13-23 Minami-Ikebukuro, Toshima-Ku, Tokyo, Japan 171-0022

TEL

03-5985-0053

Homepage URL

https://oncolo.jp/ct/oncolovirtualtrial/

Email

info_oncolo@3h-ct.co.jp


Sponsor or person

Institute

3H Clinical Trial Inc.

Institute

Department

Personal name



Funding Source

Organization

3H Clinical Trial Inc

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Japan Conference of Clinical Research

Address

Ikebukuro YS Building 8F, 1-13-23 Minami-Ikebukuro, Toshima-Ku, Tokyo, Japan 171-0022

Tel

03-6868-7022

Email

jccr-info@jccr.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2019 Year 10 Month 18 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2019 Year 10 Month 03 Day

Date of IRB

2019 Year 10 Month 17 Day

Anticipated trial start date

2019 Year 10 Month 18 Day

Last follow-up date

2020 Year 02 Month 28 Day

Date of closure to data entry

2020 Year 02 Month 28 Day

Date trial data considered complete

2020 Year 03 Month 15 Day

Date analysis concluded

2020 Year 03 Month 31 Day


Other

Other related information

ONCOLO homepage
https://oncolo.jp/

ONCOLO Virtual Trial
https://oncolo.jp/ct/oncolovirtualtrial/


Management information

Registered date

2019 Year 10 Month 18 Day

Last modified on

2020 Year 04 Month 17 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000043686


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name